Form 4: Elanco Animal Health CEO Acquires Deferred Stock Units

Jeffrey N. Simmons, CEO of Elanco Animal Health, reports acquisition of deferred stock units convertible to common stock.

Summary

• On March 21, 2025, Jeffrey N. Simmons, the CEO and a director of Elanco Animal Health Inc., acquired 262.9858 deferred stock units.
• These units represent the right to receive one share of Elanco common stock or the cash equivalent.
• The price of the derivative security is $10.53.
• Following the transaction, Simmons directly owns 15,121.5214 shares of common stock.
• The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, according to the Executive Deferral and Stock Match Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The acquisition of stock units by the CEO can be seen as a slightly positive sign of confidence, but it's not a major event.

Positives

• The CEO's acquisition of deferred stock units could be interpreted as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The deferred stock units will settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

Industry Context

Executive compensation and stock ownership are common practices in publicly traded companies to align management's interests with those of shareholders. Form 4 filings provide transparency into these transactions.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the CEO's increased stake in the company.

Key Dates

Keywords

Elanco Animal Health, Jeffrey N. Simmons, deferred stock units, Form 4, beneficial ownership, common stock, executive compensation